Kymera Investor Presentation Deck
Disease-Relevant Genes Downregulated in Skin Lesions in ≥ 50% of Evaluable*
AD (N=7) and HS (N=10) Patients at Day 28 (RNAseq)
• Substantial
downregulation of many
disease relevant genes in
both HS and AD patients
Downregulation exceeded
90% for many genes
Broad anti-inflammatory
signature with
downregulation of genes
responsible for:
KYMERA
IL1 family cytokines
Th1
Th17
Th2
Innate immunity
AD
HS
CXCL1
©2023 KYMERA THERAPEUTICS, INC.
AD-3-
AD-6-
AD-7-
AD-4-
AD-5-
AD-2-
AD-1-
IFNG
HS-3-
HS-8
HS-2-
HS-5-
HS-4-
HS-12-
HS-9-
HS-1
HS-6
HS-7
-7.5
CSF3
HS-3-
HS-8-
HS-5
HS-1-
HS-9
HS-2
HS-4-
HS-6-
HS-12-
HS-7-
0
log2(fold change)
-5.0
-7.5
-2.5 0.0
log2 (fold change)
2.5
IL2RB
0.0
AD-6-
AD-3-
AD-2-
AD-7-
AD-1-
AD-4-
AD-5-
GZMB
HS-5-
HS-2-
HS-3-
HS-8-
HS-12-
HS-6-
HS-7-
HS-4-
HS-9-
HS-1-
-3
HS-8-
HS-1-
HS-3-
HS-4-
HS-5-
HS-7-
HS-9-
HS-12-
HS-6-
HS-2-
-7.5
IL1B
-5.0
-2.5
log2 (fold change)
log2 (fold change)
tlog2(fold change): -1 = 50% decrease, -2 = 75% decrease, -3 = 87.5% decrease
log2(fold change)
-5.0
-2.5
log2(fold change)
0.0
6
2.5
IL5
AD-4-
AD-5-
AD-1-
AD-3-
AD-7-
AD-2-
AD-6-
IL8
HS-5
HS-4
HS-8
HS-1-
HS-3-
HS-12-
HS-7
HS-9
HS-6
HS-2
-5.0
IL36A
HS-5-
HS-3
HS-4
HS-1
HS-8
HS-7
HS-9-
HS-6
HS-2
HS-12-
0
-7.5
log2(fold change)
-2.5
0.0
log2 (fold change)
2.5
5.0
0.0
NLRP3
AD-3-
AD-5-
AD-2-
AD-4-
AD-7-
AD-1-
AD-6-
IL2RA
HS-4-
HS-5
HS-3-
HS-8-
HS-2-
HS-1-
HS-9-
HS-12
HS-6
HS-7
-2
IL17A
HS-5-
HS-8-
HS-3-
HS-4-
HS-1-
HS-7-
HS-2-
HS-12-
HS-9-
HS-6-
0
2
log2(fold change)
-5.0
-2.5
log2 (fold change)
log2(fold change)
*Evaluable patients for whom the samples were of sufficient quality for analysis.
0
log2(fold change)
PAGE 20View entire presentation